SCHEMBL2895902

SCHEMBL2895902

Cc1ccc(CO)cc1C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIRT3 Q9NTG7 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
EPHB4 P54760 1/20 0.41
IKBKB O14920 2/20 0.41
CHUK O15111 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NNMT P40261 1/20 0.39
PTGER4 P35408 2/20 0.38
PARP1 P09874 2/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
RPS6KB1 P23443 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5551043 0.85 MKNK1 (0.44) SIRT3TDP1EPHB4IKBKBCHUK
SCHEMBL30952718 0.85 SIRT3 (0.43) SIRT3TDP1L3MBTL1MAPK1SMN1; SMN2
SCHEMBL6831285 0.83 SIRT3 (0.42) SIRT3TDP1IKBKBL3MBTL1MAPK1
SCHEMBL5225010 0.82 HMGB1 (0.47) PTGER4MEN1KMT2A
Hydrochloric Acid SCHEMBL5129632 0.81 SIRT3 (0.41) SIRT3TDP1L3MBTL1MAPK1SMN1; SMN2
SCHEMBL13161981 0.79 KMT2A (0.40) SIRT3TDP1L3MBTL1MAPK1SMN1; SMN2
SCHEMBL27858512 0.78 KLKB1 (0.50) TDP1IKBKBCHUKPARP1MEN1
SCHEMBL22445528 0.78 ALDH1A1 (0.53) TDP1IKBKBCHUKPARP1MEN1
SCHEMBL3075763 0.78 CA12 (0.52) L3MBTL1SMN1; SMN2CYP4F2CYP4A11KMT2A
SCHEMBL2892390 0.77 ALDH1A1 (0.47) IKBKBCHUKSMN1; SMN2PARP1CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
EP-1844020-B1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS EXELIXIS INC (US) 2017-09-06 EP disclosed
EP-2137141-B1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS UNIV ABERDEEN (GB) 2015-12-02 EP disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
EP-2137141-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS The University Court of The University of Aberdeen (GB) 2009-12-30 EP disclosed
WO-2008114022-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-09-25 WO disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
EP-1844020-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS Exelixis, Inc. (US) 2007-10-17 EP disclosed
WO-2006076202-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS EXELIXIS, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 SIRT3 2395/4885TDP1 2548/4885EPHB4 1380/4885
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents ARSA, SOST, AHR SIRT3 3550/4885TDP1 3764/4885EPHB4 675/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 SIRT3 2395/4885TDP1 2548/4885EPHB4 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.